Member Info for RichMacintyre

All the regulars pumping away as they sell in the background, Avacta isn't doomed but they do need funds and keep resetting expectations, it will be years before anyone wants to buy. Red flags all over this share, Tempus reported a record $1.1 Billion, so what? JPM Conference happening, so what? Does not translate to anything to Avacta which just keeps changing targets.

17b shares, next step consolidation and placing is my bet. Rebrand necessary as last image was too toxic, change the name suck in new punters.

RSI at ~59 (neutral → bullish territory) + MACD flashing buy signals

Bouncing hard off support after that wild 52-wk range. Volume picking up on green candles.

Oversold recovery + momentum shift = classic setup for the next leg up!

Rebrand, dilute, start fresh, money on a consolidation?

Should bounce soon

Scaled in here over the past few weeks, today puts me in profit. 2026 will bring significant increases in spending on defense, war is profitable.

10% down? Why, what has happened, this one is on my radar but need a summary, whats to be expected, why the drop today, what is the forecast?

Hey folks, just wanted to share some thoughts on AVA6000 from Avacta—I've been following this one closely, and while there's some hype around the early data, I think we need to pump the brakes. Sure, the safety profile looks decent (no major cardiotoxicity like with plain old doxorubicin), but let's be real: the efficacy signals so far are pretty underwhelming for a supposed game-changer.

In the Phase 1 trials, we're talking about a measly 6% objective response rate in salivary gland cancer patients—only a couple of partial responses out of dozens, with most just holding stable or showing minor shrinks. Disease control is high at 90%, but that's not exactly blowing the doors off for refractory cancers where you'd hope for more dramatic tumor melting. And this is in a small, early cohort; bigger trials could dilute that even further.

Don't get me started on the competition— this space is crowded as hell. You've got established ADCs like Trodelvy and Enhertu already approved and pulling in big responses (20-40% ORRs in their niches), plus other FAP-targeted players like AstraZeneca's stuff or BioXcel's candidates nipping at their heels. AVA6000's peptide approach might sound clever, but it's unproven at scale and could get overshadowed fast if it doesn't deliver knockout punches.

Worse, the stock (AVCT) has absolutely tanked recently—down from over 80p mid-December to around 50p now, wiping out gains and leaving it trading at depressed levels. With cash burning and a hefty convertible loan note (CLN) hanging over them (principal still in the £20M+ range after payments), funding's gotta be a nightmare. Low share price means any new raise would be massively dilutive and risky—could spook investors even more, especially if they need to tap the market again soon to keep the lights on past Q1 2026. Partnering talks are whispered about, but nothing concrete, and in this environment, Big Pharma might lowball or walk.

I'm not saying it's doomed, but this feels like a high-risk punt with limited upside visibility right now. Anyone else seeing red flags, or am I missing something?

Mpro5 was good in its day, seen it, used it. AI bots are better faster and cheaper.

Red flags all over this.

· Pricing: Ordinary Shares shall not be sold at a price below the closing price of the Company's Ordinary Shares on the previous trading day.

So on any day if the share price rises higher than the previous day share price, even for one minute, a market maker will sell up to 25% of the weekly volume at the previous day closing price?

Meanwhile bitcoin continues to tank?

Anyone buying this share should be aware that any rise will be sold into, the bull run on crypto reserve companies is over, if you want exposure stick to ETF, SWC might be under NAV but dilution will sort that out.

Beware:

"· Additional share transactions: the New Subscription Agreement permits Shard Merchant Capital Limited, where appropriate, and with the agreement of the Company, to facilitate larger investor share purchases at market prices through the New Subscription Agreement above the volume limitation detailed above"

Nothing to stop someone shorting this to 25, 20, 15...... then buying back at market price direct from Shard.

Red Flag * "implying an effective 1.75% commission paid to Shard Merchant Capital Limited"

Shard Merchant Capital are not doing this for 1.75% profit, that would imply max profit for them of around £50thou. This is not realistic, they will work with clients who are existing shareholders sitting on losses willing to trade down to recoup their losses. Being on Aquis offers no protection from shorting if Shards clients are exististing shareholders..

The FCA should look at the list of warrant holders, previous placement subscribers, disclosed short holders and profiles on here. Its more than a smoking gun.

Hemogenyx has been on my radar for a while